biostudies-literatureUnknown15Huang XR<h4>Background</h4>Bronchopulmonary Dysplasia (BPD) is a chronic lung disease affecting preterm infants, with limited prevention and treatment options. Inhaled Nitric Oxide (iNO) is sometimes used to treat Persistent Pulmonary Hypertension of the Newborn (PPHN) and Hypoxemic Respiratory Failure (HRF), and its impact on BPD development remains debated.<h4>Objective</h4>To assess whether iNO-related factors are potential contributors to the development of BPD Grade Ⅱ-Ⅲ in very premature infants (VPI) diagnosed with PPHN or HRF at birth using Propensity Score Matching (PSM).<h4>Methods</h4>We conducted a retrospective cohort study of infants born at 22-32 weeks gestation with PPHN or HRF, treated with iNO for over 3 h. PSM matched groups by gestational age, birth weight, and gender, etc. MultFrontiers in pharmacology1515030https://www.ebi.ac.uk/biostudies/studies/S-EPMC11670073biostudies-literatureInfluence of inhaled nitric oxide on bronchopulmonary dysplasia in preterm infants with PPHN or HRF at birth: a propensity score matched study.PMC11670073Huang SQZheng ZMa LXu FLLiu LZhang JZhu YFan XFLi ZKWu FWang LDuan WLMao JWei QFYao MLFeng BYLiang GBZhu LWang MJLin XZHuang XRfalseInfluence of inhaled nitric oxide on bronchopulmonary dysplasia in preterm infants with PPHN or HRF at birth: a propensity score matched study.<h4>Background</h4>Bronchopulmonary Dysplasia (BPD) is a chronic lung disease affecting preterm infants, with limited prevention and treatment options. Inhaled Nitric Oxide (iNO) is sometimes used to treat Persistent Pulmonary Hypertension of the Newborn (PPHN) and Hypoxemic Respiratory Failure (HRF), and its impact on BPD development remains debated.<h4>Objective</h4>To assess whether iNO-related factors are potential contributors to the development of BPD Grade Ⅱ-Ⅲ in very premature infants (VPI) diagnosed with PPHN or HRF at birth using Propensity Score Matching (PSM).<h4>Methods</h4>We conducted a retrospective cohort study of infants born at 22-32 weeks gestation with PPHN or HRF, treated with iNO for over 3 h. PSM matched groups by gestational age, birth weight, and gender, etc. Mult2024-01-01T00:00:00Z20242025-04-18T22:00:35.768Z2025-04-07T09:48:24.477ZS-EPMC116700733972678910.3389/fphar.2024.1515030